Treatment Patterns, Health Care Utilization, and Costs of Ovarian Cancer in Central and Eastern Europe Using a Delphi Panel Based on a Retrospective Chart Review

Kim, Kun; Hernlund, E; Hernádi, Zoltán; Révész, János; Pete, Imre; Szánthó, András; Bodnar, Lubomir; Madry, Rodoslaw; Timorek-Lemieszczuk, Agnieszka; Božanović, Tatjana; Vasovic, S.; Tomašević, Zorica; Zivaljevic, Milica; Pazin, Vladimir; Minařík, Tomáš; Garanová, H.; Helpianska, L.; Justo, Nahila

doi:10.1097/igc.0b013e318291e8ca

Cited by 14 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over threequarters of the study population, however, was older than 70 years, and costs related to departure from the workforce may be trivial as well as insignificant from a third-party payer perspective. Unlike previous studies that have reported costs for only a fixed duration [51,52], we accounted for censoring to give an estimate of lifetime costs related to treating advanced ovarian cancer and also adjusted costs for patient and clinical characteristics. Studying lifetime treatment cost is particularly relevant in this cohort because of the high tumor recurrence rate, which may necessitate continual chemotherapeutic treatment in the continuous phase of care and contribute substantially to the overall cost of treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Extensive surveillance and many cycles of chemotherapy (maintenance or recurrence) could potentially drive high costs in this phase. Cost studies in Europe and Australia have estimated chemotherapeutic costs as the prime component of total costs when treating ovarian cancer [51,52]. Thus, when dealing with censored observations, studying lifetime costs becomes important to estimate overall disease burden.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Women with ovarian cancer consume a large proportion of healthcare resources 20 . Bangladesh has developed a pluralistic healthcare system, which includes government services, multiple NGOs and robust private sector 21 .…”

Section: Discussionmentioning

confidence: 99%

“…complex care our patients received 22 . Development of universal healthcare insurance must be part of the strategy in Bangladesh for complex care such as ovarian cancer 23,20 .…”

Section: Casementioning

confidence: 99%

Report on Three Cases of Advance Ovarian Cancer Upon Bangladeshi Population: Successful Management with Bevacizumab Based Chemotherapy

Hoque¹,

Karim

Siddiqui³

et al. 2017

Anwer Khan Mod Med Coll J

View full text Add to dashboard Cite

with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma 9 . Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks 10 . Those at very high risk may have their ovaries removed as a preventive measure 5 . If caught and treated in an early stage, ovarian cancer may be curable. Treatment usually includes some combination of surgery, Targeted therapy, radiation therapy, and chemotherapy 5 . Outcomes depend on the extent of the disease and the subtype of the cancer present 9 . The overall fiveyear survival rate in the United States is 45% 11 . Outcomes are worse in the developing world 9 . IntroductionOvarian cancer is a cancer that forms in an ovary 3 . It results in abnormal cells that have the ability to invade or spread to other parts of the body 4 . When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses 5,6 . These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others 5 . Common areas to which the cancer may spread include the lining of the abdomen, lining of the bowel and bladder, lymph nodes, lung, and liver 7,8 . The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age or reach menopause at an older age 9 . Other risk factors include hormone therapy after menopause, fertility medication, and obesity 3 . About 10% of cases are related to inherited genetic risk; women

show abstract

“…Cost-of-illness analyses of the key prosperity diseases remain rather infrequent in Eastern Europe and the Balkans region (1). Over the past decade, a few pioneering assessments were published, laying the ground for the informed decision making of local health policymakers (2).…”

Section: Introductionmentioning

confidence: 99%

Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery

Dagović

Zugic

Jakovljević

2015

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

SAŽETAK Cilj studije je analiza trendova u javnim izdvajanjima za onkolosku zdravstvenu zaštitu u godinama duboke ekonomske recesije u svetu i na Balkanu. Ostali ciljevi su utvrditi fi nu strukturu troškova u ovoj kliničkoj disciplini kao i eventualno prisustvo korelacije obima potrošnje na dijagnostiku i lečenje malignih neoplazmi sa makroekonomskim kretanjima i zdravstvenom politikom u Srbiji.Primenjena je retrospektivna studija slučaja, kojom je obuhvaćen period od cetiri godine (2010-2013.) €7, 411, 446 u 2010€7, 411, 446 u na €5, 715, 884 u 2012€7, 411, 446 u i iznova snažno skočili na €8, 536, 364 u 2013 €7, 411, 446 in 2010€7, 411, 446 in to €5, 715, 884 in 2012€7, 411, 446 in and then increased to an extraordinary €8, 536, 364 in 2013

show abstract

Treatment Patterns, Health Care Utilization, and Costs of Ovarian Cancer in Central and Eastern Europe Using a Delphi Panel Based on a Retrospective Chart Review

Cited by 14 publications

References 21 publications

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer

Report on Three Cases of Advance Ovarian Cancer Upon Bangladeshi Population: Successful Management with Bevacizumab Based Chemotherapy

Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery

Contact Info

Product

Resources

About